<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment for hormone receptor-positive, HER2-negative advanced breast cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment for hormone receptor-positive, HER2-negative advanced breast cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment for hormone receptor-positive, HER2-negative advanced breast cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cynthia X Ma, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph A Sparano, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold J Burstein, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In general, breast cancer can be broken down into three biologic subgroups, each of which has a direct bearing on treatment choices: 1) those that express the estrogen receptor (ER), 2) those that express the human epidermal growth factor receptor 2 (HER2 [with or without ER expression]), and 3) those that do not express either of these, nor the progesterone receptor (PR; triple-negative).</p><p>Although metastatic breast cancer is unlikely to be cured, there have been meaningful improvements in survival due to more effective systemic therapies, including endocrine therapy (ET) in the treatment of hormone-sensitive disease.</p><p>ET alone or in combination with targeted for metastatic hormone receptor-positive, HER2-negative breast cancer is presented here. The treatment of HER2-positive disease is discussed elsewhere, as is chemotherapy for endocrine therapy resistant, metastatic hormone receptor-positive breast cancer. Other topics including the approach to breast cancer and the role of adjunctive therapy, such as bone-modifying agents, are also covered separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)"</a> and  <a class="medical medical_review" href="/z/d/html/2798.html" rel="external">"Cancer pain management: Use of acetaminophen and nonsteroidal anti-inflammatory drugs"</a> and  <a class="medical medical_review" href="/z/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/776.html" rel="external">"Use of osteoclast inhibitors in early breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/88415.html" rel="external">"Prognostic and predictive factors in metastatic breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/775.html" rel="external">"Brain metastases in breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/2805.html" rel="external">"Radiation therapy for the management of painful bone metastases"</a>.)</p><p></p><p class="headingAnchor" id="H574404051"><span class="h1">GOALS OF THERAPY</span><span class="headingEndMark"> — </span>Patients with estrogen receptor-positive metastatic breast cancer often respond to endocrine therapy (ET) alone or in combination with targeted agents, which can reduce tumor burden and symptoms with generally fewer side effects and toxicities than chemotherapy. Furthermore, modern ETs appear to prolong progression and possibly survival compared with older ETs. However, few if any patients with metastatic breast cancer will be cured, and the goal of therapy is, principally, palliation. We choose the therapy that is most likely to stabilize or reduce the burden of disease with the fewest side effects and maintain that therapy until either unacceptable toxicities are evident or disease progression occurs.</p><p class="headingAnchor" id="H3583238095"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H46041291"><span class="h2">Types of ET and targeted agents</span><span class="headingEndMark"> — </span>There are several types of endocrine therapies (ETs), as discussed:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Strategies to deplete estrogen</strong> – In premenopausal patients, these strategies include oophorectomy or use of luteinizing hormone releasing hormone agonists and antagonists. In postmenopausal patients, estrogen is derived from adrenal precursors, testosterone, and androstenedione that are converted to <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">estradiol</a> and <a class="drug drug_general" data-topicid="107870" href="/z/d/drug information/107870.html" rel="external">estrone</a> by aromatase activity in peripheral cells. There are three aromatase inhibitors (<a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a> and <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a> are azole compounds, while <a class="drug drug_general" data-topicid="8920" href="/z/d/drug information/8920.html" rel="external">exemestane</a>, is a 17-hydroxy steroid). Randomized clinical trials in both the adjuvant and metastatic setting have demonstrated that the clinical activity, side effects, and toxicity of these three aromatase inhibitors are virtually identical, and the choice of any one of them is appropriate. (See <a class="local">'Alternative front-line options'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Strategies to directly target the ER</strong> – There are two strategies to interfere with estrogen receptor (ER) signaling: the use of selective ER modulators such as <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> or <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a>, or selective ER down-regulators. <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">Fulvestrant</a> and <a class="drug drug_general" data-topicid="140691" href="/z/d/drug information/140691.html" rel="external">elacestrant</a> down-regulate ER. (See <a class="local">'No alternations in PIK3CA, AKT1, or PTEN'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Addition of targeted agents</strong> – Addition of agents that mechanistically work in different ways than through ER interference can enhance the benefit seen with ET alone. These include cyclin-dependent kinase (CDK) 4/6 inhibitors; <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> (an inhibitor of the mechanistic target of rapamycin); and, for those with tumor phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (<em>PIK3CA</em>) mutations, <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">alpelisib</a> (an alpha isoform specific inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase) [<a href="#rid1">1</a>]. (See <a class="local">'AIs plus CDK 4/6 inhibitors'</a> below and <a class="local">'Alterations in PIK3CA, AKT1, or PTEN'</a> below.)</p><p></p><p class="headingAnchor" id="H3314276181"><span class="h2">Biopsy of a metastatic lesion</span><span class="headingEndMark"> — </span>For patients who develop metastatic disease, we biopsy a metastatic lesion.</p><p class="bulletIndent1"><span class="glyph">●</span>On the biopsy, we confirm ER, progesterone receptor (PR), and HER2 status, irrespective of whether the patient previously had early breast cancer. This is because up to 15 percent of metastatic cancers may have discordant ER measurement compared with the primary cancer [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/747.html" rel="external">"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy", section on 'Interpretation of ER and PR tests'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Approximately 20 percent of hormone receptor-positive breast cancers are also HER2 positive. These patients should receive HER2-directed therapy as part of their treatment regimen. (See  <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer", section on 'Special considerations for hormone receptor-positive disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those in whom hormone receptor positivity is confirmed, we assess tumor tissue and/or blood for <em>PIK3CA</em> and <em>ESR1</em> status, which is particularly important when making treatment decisions after disease progression on first-line CDK 4/6 inhibitor and ET. We recommend the use of multigene panel–based assays [<a href="#rid3">3</a>]. Mutations in <em>PIK3CA</em> or <em>ESR1</em> detected in either tumor tissue (preferably biopsy of a metastatic lesion) or blood are acceptable. Testing both tumor tissue and blood may increase the chance of detection [<a href="#rid4">4</a>]. Since <em>ESR1</em> mutations are often acquired after an ET-based approach and tumor evolves under treatment pressure, we recommend repeated or longitudinal genomic testing at disease progression [<a href="#rid4">4,5</a>].</p><p></p><p class="headingAnchor" id="H3065359161"><span class="h1">CHOOSING BETWEEN ENDOCRINE THERAPY AND CHEMOTHERAPY</span><span class="headingEndMark"> — </span>Our approach to endocrine versus chemotherapy in hormone receptor-positive, HER2-negative metastatic cancers is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Since endocrine therapy (ET; alone or in combination with targeted agents) is generally less toxic than chemotherapy, with comparable outcomes [<a href="#rid6">6,7</a>], it is preferable for most patients with hormone receptor-positive disease to begin treatment with ET.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the minority of patients who have extensive visceral metastases, chemotherapy may be considered an appropriate alternative to ET plus targeted agents; however, there are no data suggesting a survival benefit to this approach.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one randomized phase II trial (RIGHT Choice study), in 222 pre- or perimenopausal patients with aggressive, hormone receptor-positive, HER2-negative breast cancer (half of whom had visceral crisis), initial ET plus <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">ribociclib</a> improved progression-free survival relative to combination chemotherapy (24.0 versus 12.3 months, hazard ratio [HR] 0.54, 95% CI 0.36-0.79), with similar response rates (65 versus 60 percent) and fewer grade 3 to 4 adverse events (0.9 versus 7.0 percent) [<a href="#rid8">8</a>]. Time to tumor response was 4.9 months in the ET/ribociclib arm versus 3.2 months with chemotherapy, but this difference was not statistically significant. Overall survival results are pending. Although these results support frontline ET plus a CDK 4/6 inhibitor for patients with aggressive hormone receptor-positive, HER2-negative disease, we note that the majority of patients in this trial had de novo metastatic disease. Many patients treated in the United States have received prior treatments in the neoadjuvant/adjuvant setting. (See  <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Special considerations for those with rapidly progressive disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no data that combining ET (with or without targeted agents) with chemotherapy improves overall survival, and therefore we do not use this strategy [<a href="#rid9">9</a>].</p><p></p><p class="headingAnchor" id="H3381109894"><span class="h1">CONSIDERATIONS FOR THOSE WHO RECEIVED ADJUVANT ET</span></p><p class="bulletIndent1"><span class="glyph">●</span>Women who progress ≥12 months from the end of adjuvant endocrine therapy (ET) and patients who present with de novo metastatic breast cancer are offered first-line ET or ET in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor. (See <a class="local">'Preferred first-line therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those who progress on or within 12 months of completing adjuvant ET are eligible for subsequent-line ET in combination with a CDK 4/6 inhibitor. (See <a class="local">'Subsequent-line options'</a> below.)</p><p></p><p class="headingAnchor" id="H146248622"><span class="h1">PREFERRED FIRST-LINE THERAPY</span></p><p class="headingAnchor" id="H173314759"><span class="h2">AIs plus CDK 4/6 inhibitors</span><span class="headingEndMark"> — </span>Our preferred initial regimen is a cyclin-dependent kinase (CDK) 4/6 inhibitor with an aromatase inhibitor (AI). Premenopausal women must have ovarian suppression/ablation when on AIs. (See <a class="local">'Ovarian suppression/ablation, in combination with ET'</a> below.)</p><p class="headingAnchor" id="H2448420687"><span class="h3">Rationale for use of a CDK 4/6 inhibitor</span><span class="headingEndMark"> — </span>Among postmenopausal women with hormone receptor-positive breast cancer, combinations of the AI <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a> with CDK 4/6 inhibitors (<a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">palbociclib</a>, <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">ribociclib</a>, or <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a>) have demonstrated improved progression-free survival (PFS) relative to an AI alone [<a href="#rid10">10</a>], and have been approved by the US Food and Drug Administration (FDA) in this setting. The addition of ribociclib to an AI has also shown overall survival (OS) benefits. Furthermore, in a meta-analysis of nine randomized trials with over 5000 postmenopausal patients, the addition of CDK 4/6 inhibitors to ET improved OS (hazard ratio [HR] 1.33, 95% CI 1.19-1.48), but increased risks of neutropenia, leukopenia, and diarrhea [<a href="#rid11">11</a>]. The CDK 4/6 inhibitors have not been directly compared in clinical trials. Available trials are summarized in the table  (<a class="graphic graphic_table graphicRef141032" href="/z/d/graphic/141032.html" rel="external">table 1</a>).</p><p>Although we typically incorporate CDK 4/6 inhibitors in first-line treatment paradigms, there are data to support deferring to the second-line setting. Although this is not our preferred treatment strategy, it is a reasonable option to consider for those with endocrine sensitive disease (ie, metastatic recurrence occurred &gt;12 months from adjuvant endocrine therapy) who prefer to avoid initial treatment with a CDK 4/6 inhibitor (eg, due to concerns regarding toxicity, financial considerations, or need for radiation to symptomatic sites of disease).</p><p>The SONIA trial was developed by the Danish government as a cost containment strategy and randomly assigned 1050 women to either first-line treatment with a nonsteroidal aromatase inhibitor (NSAI) plus a CDK 4/6 inhibitor, followed by single-agent <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> upon disease progression; or to first-line treatment with an NSAI followed thereafter by fulvestrant plus a CDK 4/6 inhibitor upon progression [<a href="#rid12">12</a>]. At a median follow up of 37 months, median overall survival was 46 months in the first-line CDK 4/6 inhibitor group and 54 months in the second line CDK 4/6 inhibitor group (HR 0.98, 95% CI 0.80-1.20). The first-line group remained on CDK 4/6 inhibitor for 25 months, versus 8.1 months for the second-line group, which was associated with an increase in drug expenditure of 200,000 dollars per patient. Given the longer time on CDK 4/6 inhibition, there were 42 percent more grade ≥3 toxicities with first-line CDK 4/6 inhibition (2782 versus 1620 events).</p><p>A caveat to interpretation of this study is that the first-line CDK 4/6 inhibitor group received single-agent <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> in the second-line, which is no longer what most patients receive given the emergence of other targeted agents (eg, <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">alpelisib</a>, <a class="drug drug_general" data-topicid="140691" href="/z/d/drug information/140691.html" rel="external">elacestrant</a>). Nevertheless, deferring the CDK 4/6 inhibitor to the second-line setting is an appropriate strategy in select patients. Data regarding initial treatment with single-agent aromatase inhibitors are found below. (See <a class="local">'Alternative front-line options'</a> below.)</p><p class="headingAnchor" id="H3900147893"><span class="h3">Choosing between agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choosing between CDK 4/6 inhibitors</strong> – There is controversy regarding the choice of CDK 4/6 inhibitors. We consider any of the three CDK 4/6 inhibitors to be acceptable options, with a choice between them driven by efficacy and toxicity profile of the agents. <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">Palbociclib</a> and <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">ribociclib</a> are associated with higher rates of neutropenia than <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a>, whereas abemaciclib more frequently causes diarrhea  (<a class="graphic graphic_table graphicRef141032" href="/z/d/graphic/141032.html" rel="external">table 1</a>). Ribociclib has a higher incidence of liver function test abnormalities than the other agents and can cause QTc prolongation, and therefore may be less preferred for some patients (eg, those on QTc-prolonging agents).</p><p></p><p class="bulletIndent1">Of the three agents, <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a> has been evaluated in patients with brain metastases and may be preferred in this setting. However, this is a very rare occurrence in first- or second-line treatment of hormone receptor-positive breast cancer. Data are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/775.html" rel="external">"Brain metastases in breast cancer", section on 'Other options in specific subsets'</a>.)</p><p></p><p class="bulletIndent1">Overall survival data have emerged from the randomized trials of CDK 4/6 inhibitors in combination with an AI:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">Ribociclib</a> has demonstrated OS benefit when added to an AI or AI plus ovarian function suppression in the MONALEESA-2 (64 months versus 51 months, HR 0.76, 95% CI 0.63-0.93) [<a href="#rid13">13</a>] and MONALEESA-7 trials (58 months versus 48 months, HR 0.76, 95% CI 0.61-0.96) [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">palbociclib</a> did not demonstrate OS benefit in the PALOMA-2 trial (54 months versus 51 months, HR 0.96, 95% CI 0.78-1.2) [<a href="#rid15">15</a>], there were significant missing follow-up data that were imbalanced between the arms. Combined analysis of PALOMA-1 and PALOMA-2 did show OS benefit in the group that had disease-free interval over 12 months [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In MONARCH 3, there was a trend toward longer OS with the addition of <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a> to an AI (median 67 versus 54 months; HR 0.80, 95% CI 0.64-1.02), which did not reach statistical significance [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">In preclinical studies, <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">ribociclib</a> and <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a> are four- and five-times more selective toward CDK 4 over CDK 6 and abemaciclib has a broader CDK target including cyclin B–CDK1, cyclin A/E–CDK2, and cyclin T–CDK9 [<a href="#rid18">18</a>], suggesting potential differences among the three different CDK 4/6 inhibitors. Nevertheless, we consider each agent to be an acceptable option.</p><p></p><p class="bulletIndent1">Novel CDK 4/6 inhibitors (eg, dalpiciclib) are under investigation [<a href="#rid19">19</a>], with promising results.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choosing between AIs</strong> – Although the AIs have not been compared when combined with a common CDK 4/6 inhibitor, randomized trials of single-agent AIs demonstrate that no one AI is better than the others. In one trial of 128 women with advanced breast cancer, <a class="drug drug_general" data-topicid="8920" href="/z/d/drug information/8920.html" rel="external">exemestane</a> and <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a> resulted in a similar objective response rate (15 percent in both groups) and OS (31 and 33 months, respectively) [<a href="#rid20">20</a>]. Although pharmacokinetic data suggest that <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a> is a more effective AI, other data suggest that once a certain threshold of aromatase inhibition is reached, differences in estrogen suppression between the AIs are not associated with clinically significant differences in efficacy [<a href="#rid21">21,22</a>].</p><p></p><p class="headingAnchor" id="H2872486808"><span class="h2">Alternative front-line options</span><span class="headingEndMark"> — </span>Acceptable alternatives to AIs plus CDK 4/6 inhibitors are discussed below. Ovarian suppression or ablation is added for premenopausal women. (See <a class="local">'Ovarian suppression/ablation, in combination with ET'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fulvestrant</strong><strong> monotherapy</strong> – <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">Fulvestrant</a> is an alternative option, but is less preferable than front-line AI and CDK 4/6 inhibition.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">Fulvestrant</a> is an ER antagonist that blocks ER dimerization and DNA binding, increases ER turnover, and inhibits nuclear uptake of the receptor [<a href="#rid23">23-25</a>]. Fulvestrant is administered as an intramuscular injection (500 mg loading dose on days 1, 14, and 29 of the first month, then maintenance dosing monthly at day 28, ±3 days).</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">Fulvestrant</a> monotherapy has never been compared with the combination of an AI and a CDK 4/6 inhibitor. However, in the phase III FALCON trial, fulvestrant 500 mg improved PFS over <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a> at a median follow-up of 25 months (16.6 versus 13.8 months; HR for progression or death 0.80, 95% CI 0.637-0.999) [<a href="#rid26">26</a>]. There was no benefit in OS. Quality of life outcomes were similar between the two groups, with the most common adverse effects being arthralgia (17 versus 10 percent) and hot flashes (11 versus 10 percent) for fulvestrant and anastrozole, respectively. Previous studies using lower doses of fulvestrant (250 mg) showed equivalent PFS between fulvestrant and AIs [<a href="#rid27">27-30</a>], and therefore the higher dose is preferred.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fulvestrant</strong><strong> plus a CDK 4/6 inhibitor</strong> – <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">Fulvestrant</a> plus a CDK 4/6 inhibitor may be an option for those who do not tolerate AI-based therapy.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">Fulvestrant</a> plus <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">palbociclib</a> was compared with <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a> plus palbociclib in a randomized trial in 486 patients with previously treatment-naive, hormone receptor-positive, HER2-negative advanced breast cancer [<a href="#rid31">31</a>]. Median PFS was 27.9 months for fulvestrant-palbociclib versus 32.8 months for letrozole-palbociclib, a difference that was not statistically significant.</p><p></p><p class="bulletIndent1">A trial evaluating <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> plus the CDK 4/6 inhibitor <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">ribociclib</a> included treatment-naïve patients, as well as those with prior lines of ET, and is discussed below. (See <a class="local">'For those on an AI alone, or relapse on or soon after adjuvant AI'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an FDA pooled analysis, in two trials evaluating the combination of CDK 4/6 inhibitors or placebo in combination with <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> (396 patients), the estimated HR for overall survival was 0.74 (95% CI 0.52-1.07) favoring addition of CDK 4/6 inhibitors [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fulvestrant</strong><strong> plus </strong><strong>anastrozole</strong> – The combination of <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> plus <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a> is an acceptable alternative to the AI/CDK 4/6 inhibitor combination for the patient who presents with de novo metastatic breast cancer (and is therefore ET naïve).</p><p></p><p class="bulletIndent1">Several trials investigating the combination of <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> plus <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a> versus anastrozole alone have been published, but with discrepant results [<a href="#rid33">33-36</a>]. PFS and OS benefits, when present, appeared to be greatest in those with de novo metastatic disease [<a href="#rid36">36</a>]. Of note, in these trials, fulvestrant was administered at a dose of 250 mg monthly, which is lower than the currently approved prescribed dose. Examples of these trials are discussed below:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AI monotherapy</strong> – For patients who have not received an aromatase inhibitor (AI) in the adjuvant setting and are unlikely to tolerate a CDK 4/6 inhibitor, AI monotherapy is an appropriate alternative. Although <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> as a single-agent has shown better activity than aromatase inhibition, some patients may prefer oral therapy to intramuscular injection.</p><p></p><p class="bulletIndent1">The efficacy of AIs as a first-line treatment for advanced or metastatic breast cancer and their OS superiority to <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> in postmenopausal women were shown in a 2006 meta-analysis of 23 randomized trials (n = 8504 patients) [<a href="#rid37">37</a>]. Treatment with an AI resulted in an improvement in OS compared with tamoxifen (HR 0.89, 95% CI 0.80-0.99) and with other ETs (HR 0.87, 95% CI 0.82-0.93).</p><p></p><p class="headingAnchor" id="H1429233341"><span class="h1">RESISTANCE TO TREATMENT</span><span class="headingEndMark"> — </span>The presence of new metastatic lesions, clinical deterioration, or growth of lesions suggests a given treatment is not working. Appropriate monitoring, duration of treatment, and definition of failure is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Monitoring therapy'</a> and  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Duration of treatment'</a> and  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Definition of treatment failure'</a>.)</p><p>When a patient's cancer fails to respond or stops responding to a given line of endocrine therapy (ET) or a targeted agent, an important consideration is whether or not to proceed with another line of ET (with or without a targeted agent) or move to chemotherapy. The relative level of estrogen receptor (ER) in the tissue (1 to 9 versus ≥10 percent), the duration of response to the prior ET or targeted therapy, the patient's tolerance of prior therapy, and the presence or absence of rapidly progressive visceral disease should all factor into the decision regarding whether to proceed with another line of ET/targeted therapy or move to chemotherapy. We often offer patients two to three lines of ET (including targeted agents) before moving to chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer"</a>.)</p><p>Many possible reasons exist for resistance to ET. For example, studies have suggested that up to 30 percent of metastatic ER-positive breast cancers may have activating mutations in the estrogen-binding domain of the gene that encodes for ER (<em>ESR1</em>) [<a href="#rid38">38,39</a>]. In this case, these cancers may be resistant to estrogen depletion (eg, aromatase inhibitors), but they may better respond to ER-targeting therapies such as <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> or <a class="drug drug_general" data-topicid="140691" href="/z/d/drug information/140691.html" rel="external">elacestrant</a>. Elacestrant is superior to fulvestrant for the treatment of <em>ESR1</em> mutated breast cancer. (See <a class="local">'ESR1 mutation-positive'</a> below.)</p><p class="headingAnchor" id="H882605031"><span class="h1">SUBSEQUENT-LINE OPTIONS</span><span class="headingEndMark"> — </span>The optimal sequence upon progression on ET is not well defined, and multiple strategies are possible. Our approach is outlined in the sections below, and takes into account the patient's previous treatment history and the side effect profiles of treatment.</p><p class="headingAnchor" id="H2722547050"><span class="h2">After an AI plus CDK 4/6 inhibitor</span></p><p class="headingAnchor" id="H3668197114"><span class="h3">No alternations in PIK3CA, AKT1, or PTEN</span></p><p class="headingAnchor" id="H2787301749"><span class="h4">ESR1 wild-type</span><span class="headingEndMark"> — </span>For patients with <em>PIK3CA</em> and <em>ESR1</em> wild-type tumors who have experienced progression on an aromatase inhibitor (AI) plus cyclin-dependent kinase (CDK) 4/6 inhibitor, we suggest the selective estrogen receptor degrader (SERD) <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a>, with or without the mechanistic target of rapamycin (mTOR) inhibitor <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>.</p><p>In rare instances, breast cancers have HER2 mutations (not gene amplifications) on genomic sequencing. For ER positive tumors with HER2 mutations, <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> in combination with anti-HER2 therapy with <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> and <a class="drug drug_general" data-topicid="114008" href="/z/d/drug information/114008.html" rel="external">neratinib</a> is another treatment option. For patients who received a nonsteroidal AI (<a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a>, <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a>), another alternative is <a class="drug drug_general" data-topicid="8920" href="/z/d/drug information/8920.html" rel="external">exemestane</a> plus <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>. A choice between these options is driven by patient preferences, considering the side-effect profile of everolimus, which includes mucositis, rash, fatigue, diarrhea, and pneumonitis. For patients who develop shortness of breath or increase in cough, everolimus should be held and patients assessed for pneumonitis. A brief course of steroids may be necessary. Additional information on the toxicity of everolimus is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Rapamycin and analogs'</a> and  <a class="medical medical_review" href="/z/d/html/1152.html" rel="external">"Oral toxicity associated with systemic anticancer therapy", section on 'Dexamethasone mouthwash'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fulvestrant</strong> – In the endocrine therapy (ET)-refractory setting, <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> monotherapy has shown equivalent activity as <a class="drug drug_general" data-topicid="8920" href="/z/d/drug information/8920.html" rel="external">exemestane</a> in postmenopausal women with hormone receptor-positive disease who had progressed on a nonsteroidal AI [<a href="#rid29">29</a>]. However, the lower maintenance dose of fulvestrant was used in this trial (250 mg), and it is expected that the higher dose (500 mg) would lead to improved outcomes, based on a separate trial comparing the doses [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fulvestrant</strong><strong> plus </strong><strong>everolimus</strong> – This combination has been studied in patients with progression after an AI, but not after an AI/CDK 4/6 inhibitor combination.</p><p></p><p class="bulletIndent1">Results from the randomized phase II PrE0102 trial suggest the combination of <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> and <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> may also be an effective strategy for patients resistant to AIs, with a doubling in progression-free survival (PFS) compared with fulvestrant alone (10.3 versus 5.1 months; hazard ratio [HR] 0.61, 95% CI 0.4-0.92) [<a href="#rid41">41</a>]. Adverse events of all grades occurred more often in the everolimus arm, including oral mucositis (53 versus 12 percent), fatigue (42 versus 22 percent), rash (38 versus 5 percent), anemia (31 versus 6 percent), and diarrhea (23 versus 8 percent), although grade 3 to 4 events were uncommon. Similar results were found in the MANTA trial (median PFS 12.2 versus 4.6 months, with and without everolimus) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fulvestrant</strong><strong> plus </strong><strong>neratinib</strong><strong> and </strong><strong>trastuzumab</strong><strong>, for cancers with HER2-activating mutations</strong> – For patients with hormone receptor positive, HER2-negative metastatic breast cancer with activating <em>HER2</em> mutation(s) and prior CDK 4/6 inhibitor therapy, <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> plus <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> and <a class="drug drug_general" data-topicid="114008" href="/z/d/drug information/114008.html" rel="external">neratinib</a> is an acceptable option, and has been associated with an objective response rate of 39 percent and median PFS of 8.3 months in this population [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternatives to </strong><strong>fulvestrant</strong><strong>-based therapy</strong> – For patients who prefer to avoid the intramuscular injections of <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a>, alternatives exist. Studies show that <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> pairs effectively with an AI or <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>, for the treatment of AI-resistant, advanced, estrogen receptor (ER)-positive breast cancer. Activating mutations in the alpha isoform of the catalytic subunit of <em>PIK3CA</em> and PIK3CA/AKT/mTOR pathway activation status are not predictive of benefit from everolimus.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Everolimus</strong><strong> plus AI</strong> – The benefit of <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> plus <a class="drug drug_general" data-topicid="8920" href="/z/d/drug information/8920.html" rel="external">exemestane</a> over exemestane alone was shown in the BOLERO-2 trial, which enrolled 724 women who had progressed on <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a>. Patients randomly assigned to exemestane (25 mg daily) and everolimus (10 mg daily) experienced an improvement in PFS (7 versus 3 months; HR for mortality 0.45, 95% CI 0.35-0.54) and objective response rate (ORR; 9.5 versus 0.4 percent) relative to those receiving exemestane alone, although there was no difference in OS (31 versus 26.6 months; HR 0.89, 95% CI 0.73-1.10) [<a href="#rid44">44,45</a>]. Everolimus was associated with serious side effects (grade 3/4), including stomatitis (8 percent), dyspnea (4 percent), noninfectious pneumonitis (3 percent), and elevated liver enzymes (3 percent) [<a href="#rid44">44,45</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Everolimus</strong><strong> plus </strong><strong>tamoxifen</strong> – The combination of <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> plus <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> is another option for patients previously treated with an AI, and may be preferable for those who were previously poorly tolerant of AI treatment. In a study conducted by GINECO, 111 postmenopausal women who had progressed on an AI were randomly assigned treatment with tamoxifen with or without everolimus [<a href="#rid46">46</a>]. Compared with tamoxifen alone, combination treatment with everolimus resulted in an improvement in time to progression (8.6 versus 4.5 months; HR 0.54, 95% CI 0.36-0.81) and risk of death (HR 0.45, 95% CI 0.24-0.81). Incidence of serious pain or fatigue was also reduced. There was no difference in ORR (14 versus 13 percent). Combination treatment resulted in higher incidence of grade 3 or 4 stomatitis (11 versus 0 percent) and any-grade pneumonitis (17 versus 4 percent), though grade 3/4 toxicity was rare in either group.</p><p></p><p>Data are insufficient to support a CDK 4/6 inhibitor plus <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> after progression on an AI and CDK 4/6 inhibitor. Trials have not found benefit with continuation of a CDK 4/6 inhibitor with second-line endocrine therapy compared with second-line endocrine therapy alone, among patients with prior progression on first-line endocrine therapy with a CDK 4/6 inhibitor [<a href="#rid47">47,48</a>].</p><p class="headingAnchor" id="H449669600"><span class="h4">ESR1 mutation-positive</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="140691" href="/z/d/drug information/140691.html" rel="external">Elacestrant</a> (aka RAD1901) is a SERD that has regulatory approval in the United States for use in postmenopausal women and in men with <em>ESR1</em>-mutated advanced hormone receptor-positive, HER2-negative breast cancer that has progressed on at least one line of prior ET [<a href="#rid49">49</a>]. Given PFS benefits over <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a>, as well as the ease of oral administration, we suggest its use in this setting, particularly in patients who experienced prolonged PFS on the prior lines of ET and CDK 4/6 inhibitors.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elacestrant</strong> – In the EMERALD trial, <a class="drug drug_general" data-topicid="140691" href="/z/d/drug information/140691.html" rel="external">elacestrant</a> was compared against standard of care (SOC) ET (investigator's choice of <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> or an AI) among 477 patients who had received one or two prior lines of ET and up to one line of chemotherapy in the metastatic setting, and who had progressed on prior treatment with a CDK 4/6 inhibitor [<a href="#rid50">50</a>]. The majority of patients in the SOC group received fulvestrant. At 12 months, the elacestrant group had a better PFS rate than the SOC group and those specifically receiving fulvestrant (22 versus 9 and 10 percent, respectively). Greater PFS improvements were observed in the subgroup with<em> ESR1</em> mutations with elacestrant versus SOC and fulvestrant (12-month PFS rates of 27 versus 8.2 and 8.4 percent, respectively). Benefit of elacestrant is more marked in patients who experienced longer PFS on the prior ET plus CDK 4/6 inhibitor (likely more endocrine sensitive disease) [<a href="#rid51">51</a>]. Among patients who were on prior a CDK 4/6 inhibitor for at least 12 months, the median PFS was 8.6 months on elacestrant versus 1.9 months on SOC ET (HR 0.41). Overall survival results were immature, but there was a trend favoring elacestrant.</p><p></p><p class="bulletIndent1">The most frequent toxicity with <a class="drug drug_general" data-topicid="140691" href="/z/d/drug information/140691.html" rel="external">elacestrant</a> was nausea, occurring in 35 percent. Grade ≥3 adverse events were observed among 7 percent of patients in the elacestrant arm and 3 percent in the SOC arm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational strategies</strong> – The PADA1 trial found that, among patients who develop a blood <em>ESR1</em> mutation on an AI plus a CDK 4/6 inhibitor, a switch from the AI to <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> (with the same CDK 4/6 inhibitor) before clinical progression improved PFS over continuation of the AI/CDK 4/6 inhibitor [<a href="#rid52">52</a>]; but effect on OS was uncertain. We await further prospective data prior to using this strategy in routine clinical practice.</p><p></p><p class="bulletIndent1">Lasofoxifene is an orally administered selective ER modulator under investigation in <em>ESR1 </em>mutated cancers and has shown promise [<a href="#rid53">53,54</a>].</p><p></p><p class="headingAnchor" id="H673923302"><span class="h3">Alterations in PIK3CA, AKT1, or PTEN</span><span class="headingEndMark"> — </span>The phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR) signaling pathway plays a critical role in mediating cell growth, survival, and angiogenesis. Mutations in components of the PI3K pathway are frequently observed in ER-positive breast cancer. Specifically, mutations in<em> PIK3CA</em>, which encodes the alpha isoform of the catalytic subunit of PI3K, are detected in over 40 percent of ER-positive breast cancers [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H1646012117"><span class="h4">Preferred: Fulvestrant plus capivasertib</span><span class="headingEndMark"> — </span>For patients with hormone receptor-positive, HER2-negative advanced breast cancer with one or more alterations in <em>PIK3CA</em>/<em>AKT1</em>/<em>PTEN </em>who have experienced progression on at least one endocrine-based regimen in the metastatic setting, or recurrence on or within 12 months of completing adjuvant therapy, the AKT inhibitor <a class="drug drug_general" data-topicid="143510" href="/z/d/drug information/143510.html" rel="external">capivasertib</a> has regulatory approval by the US Food and Drug Administration (FDA) in combination with <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> [<a href="#rid56">56</a>]. As such, patients with tumors harboring activating <em>PIK3CA </em>mutations are eligible for fulvestrant with either capivasertib or <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">alpelisib</a>. There have been no head-to-head trials of these strategies. As such, either alpelisib or capivasertib are acceptable options, but we have a preference for capivasertib, based on seemingly better tolerability, including lower rates of hyperglycemia.</p><p>A randomized phase III trial (CAPItello-291) has shown PFS benefits with the addition of <a class="drug drug_general" data-topicid="143510" href="/z/d/drug information/143510.html" rel="external">capivasertib</a> to <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> therapy among patients with progression on a previous AI, with or without a CDK 4/6 inhibitor [<a href="#rid57">57</a>]. Among 708 patients, the median PFS was 7.2 months in the capivasertib–fulvestrant group versus 3.6 months in the placebo–fulvestrant group (HR 0.60, 95% CI 0.51-0.71). Among patients with PI3K pathway–altered (<em>PIK3CA</em>, <em>AKT1</em>, or <em>PTEN</em>) tumors, benefits were comparable (PFS 7.3 versus 3.1 months; HR 0.50, 95% CI 0.38-0.65). The estimated OS at 18 months was 74 percent with capivasertib–fulvestrant and 65 percent with placebo–fulvestrant in the overall population (HR 0.74, 95% CI 0.56-0.98); and 73 versus 63 percent, respectively, in the <em>AKT</em> pathway–altered population (HR 0.69, 95% CI 0.45-1.05). While the outcomes in patients previously treated with a CDK 4/6 inhibitor also favored capivasertib, the absolute gains in PFS were smaller than in the overall group.</p><p>Although benefits were observed in the overall population, the previous randomized phase II FAKTION study demonstrated that benefit was limited to tumors with <em>AKT1</em>/<em>PTEN</em>/<em>PIK3CA</em> mutations. In this study, among the 76 patients with pathway-altered tumors, the addition of <a class="drug drug_general" data-topicid="143510" href="/z/d/drug information/143510.html" rel="external">capivasertib</a> to <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> improved median PFS (12.8 months compared with 4.6 months with placebo; HR 0.44, 95% CI 0.26-0.72) [<a href="#rid58">58</a>]. OS was 39 versus 20 months, respectively (adjusted HR 0.46, 95% CI 0.27-0.79). PFS and OS benefits were not observed among the 64 patients lacking pathway alterations. Regulatory approval has only been granted in the United States to patients whose tumors harbor alterations in <em>PIK3CA</em>, <em>AKT1</em>,<em> </em>or <em>PTEN.</em></p><p>The most frequent grade ≥3 adverse events in the <a class="drug drug_general" data-topicid="143510" href="/z/d/drug information/143510.html" rel="external">capivasertib</a>–<a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> group were rash (12 percent) and diarrhea (9.3 percent). Grade ≥3 hyperglycemia occurred in 2.3 percent. Adverse events leading to discontinuation were reported in 13 percent of the patients receiving capivasertib and in 2.3 percent of those receiving placebo.</p><p>The improvement in overall survival is encouraging; other targeted agents of the <em>AKT </em>pathway including <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">alpelisib</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> have not yet shown such benefits. Longer term data are needed to confirm a survival benefit.</p><p class="headingAnchor" id="H1310900260"><span class="h4">Alternative in PIK3CA mutant tumors: Fulvestrant plus alpelisib</span><span class="headingEndMark"> — </span>For those with tumor <em>PIK3CA</em> mutations whose cancers have progressed on or after treatment with an AI, the combination of the alpha isoform-specific PI3K inhibitor <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">alpelisib</a> and <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> is an appropriate alternative to fulvestrant/<a class="drug drug_general" data-topicid="143510" href="/z/d/drug information/143510.html" rel="external">capivasertib</a>. (See <a class="local">'Preferred: Fulvestrant plus capivasertib'</a> above.)</p><p>In a phase III trial of 572 men and postmenopausal patients with advanced hormone receptor-positive breast cancer, all of whom had received a prior AI either for local or advanced disease, <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">alpelisib</a> plus <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> improved PFS relative to fulvestrant alone among those with tum<em>or PIK3CA </em>mutations (11.0 versus 5.7 months; HR 0.65, 95% CI 0.50-0.85) [<a href="#rid59">59</a>]. Median OS was 39 months for alpelisib-fulvestrant and 31 months for placebo-fulvestrant (HR 0.86, 95% CI 0.64-1.15) [<a href="#rid60">60</a>]. In the cohort without tumor<em> PIK3CA</em> mutations, the median PFS was 7.4 months in the alpelisib-fulvestrant group and 5.6 months in the fulvestrant-only group (HR 0.85, 95% CI 0.58-1.25). In the overall population, the most frequent adverse grade 3 or 4 events in the alpelisib-fulvestrant versus fulvestrant-only group, respectively, included hyperglycemia (37 and 0.7 percent), rash (10 and 0.3 percent), and diarrhea (7 and 0.3 percent). Permanent discontinuation of alpelisib or placebo due to adverse events occurred in 71 patients (25 percent) receiving alpelisib-fulvestrant and in 12 (4.2 percent) receiving placebo-fulvestrant.</p><p>However, this trial included a limited number of patients with prior therapy with CDK 4/6 inhibitors. Results from a single-arm phase II study in 127 patients with tumor <em>PIK3CA</em> mutations and prior AI/CDK 4/6 inhibitor treatment suggest activity of <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> and <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">alpelisib</a> in this population, with approximately 50 percent of patients not progressing after six months on treatment [<a href="#rid61">61</a>].</p><p><a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">Alpelisib</a> is associated with several important side effects that led to a 25 percent rate of permanent treatment discontinuation in the SOLAR1 trial, including stomatitis, diarrhea, rash, and hyperglycemia. Strategies for prevention and management of adverse events is described in the tables  (<a class="graphic graphic_table graphicRef132328" href="/z/d/graphic/132328.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef132329" href="/z/d/graphic/132329.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef132330" href="/z/d/graphic/132330.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef132331" href="/z/d/graphic/132331.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef132333" href="/z/d/graphic/132333.html" rel="external">table 6</a>). Our approach is to treat hyperglycemia with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> as it arises on alpelisib; however, an acceptable alternative is to administer prophylactic metformin, particularly for those at high risk of hyperglycemia [<a href="#rid62">62</a>]. In one non-randomized phase II trial in 68 patients with normal baseline fasting glucose or pre-diabetic HbA1c level, prophylactic metformin beginning with initiation of alpelisib was associate with a low rate of grade 3 to 4 hyperglycemia by cycle 2 of alpelisib/<a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> therapy (5.9 percent), which compares favorably with that observed in the SOLAR1 trial (37 percent) [<a href="#rid63">63</a>].</p><p>A separate investigational strategy using the novel alpha isoform-specific PI3K inhibitor and degrader inavolisib with <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">palbociclib</a> and <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> has shown promise in endocrine therapy resistant <em>PIK3CA</em>-mutated, hormone receptor positive, HER2-negative breast cancer. In 325 such patients who experienced recurrence on or within 12 months of adjuvant endocrine therapy, median PFS was 15 months with inavolisib, palbociclib, and fulvestrant and 7.3 months with placebo, palbociclib, and fulvestrant (HR 0.43, 95% CI 0.32-0.59) [<a href="#rid64">64</a>]. There was a trend favoring OS as well that did not reach statistical significance, although survival data are immature (median OS not estimable versus 31 months respectively; stratified HR 0.64, 95% CI 0.43-0.97). Grade ≥3 adverse events with inavolisib versus placebo were neutropenia (80 versus 78 percent), thrombocytopenia (14 versus 4.3 percent), leukopenia (6.8 versus 11 percent), and anemia (6.2 versus 1.9 percent). Grade ≥3 adverse events that were seen with inavolisib but not placebo included hyperglycemia (5.6 percent), diarrhea (3.7 percent), and stomatitis and mucosal inflammation (5.6 percent). Inavolisib is not as yet approved for any indication.</p><p>Earlier trials evaluating combinations of <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> with either pan-isoform PI3K inhibitors (eg, buparlisib and pictilisib) or the beta isoform-sparing agent taselisib suggested limited improvements in PFS in patients with ET-resistant disease, but a narrow therapeutic window due to toxicities (eg, gastrointestinal side effects, transaminitis, and hyperglycemia [<a href="#rid65">65-70</a>]). Buparlisib was also associated with anxiety and depression [<a href="#rid65">65-67</a>].</p><p class="headingAnchor" id="H812367331"><span class="h2">For patients treated with other initial strategies</span></p><p class="headingAnchor" id="H1234205302"><span class="h3">For those on an AI alone, or relapse on or soon after adjuvant AI</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">Fulvestrant</a> plus a CDK 4/6 inhibitor is often chosen as next-line therapy for patients previously treated with an aromatase inhibitor (AI) alone; or who experience relapse on an adjuvant AI or within 12 months of completing an adjuvant AI  (<a class="graphic graphic_table graphicRef141033" href="/z/d/graphic/141033.html" rel="external">table 7</a>). If an <em>ESR1 </em>mutation is present, <a class="drug drug_general" data-topicid="140691" href="/z/d/drug information/140691.html" rel="external">elacestrant</a> is a reasonable alternative. (See <a class="local">'ESR1 mutation-positive'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for incorporating CDK 4/6 inhibition</strong> – In a US Food and Drug Administration pooled analysis including three trials, among patients who were assigned to <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a>/CDK 4/6 inhibitors or fulvestrant/placebo as second-line or later-line ET, the CDK 4/6 inhibitor group experienced an improvement in overall survival (HR 0.77, 95% CI 0·67-0·89) [<a href="#rid32">32</a>]. The difference in estimated median overall survival was seven months, favoring CDK inhibitors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choosing between CDK 4/6 inhibitors</strong> – Both <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">palbociclib</a> and <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a> are approved for use in combination with <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> in the subsequent-line setting in the United States. <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">Ribociclib</a> is approved for use with fulvestrant either in the first-line or subsequent-line setting. These are all appropriate combinations in patients with previous AI treatment.</p><p></p><p class="bulletIndent1">In a separate network meta-analysis, no statistically significant differences in PFS were found among the three CDK 4/6 inhibitors in combination with <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a>: <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">palbociclib</a> versus <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a> (HR 0.83), palbociclib versus <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">ribociclib</a> (HR 0.77, 95% CI 0·44-1·35), and abemaciclib versus ribociclib (HR 0.93) [<a href="#rid71">71</a>]. However, this conclusion is based on cross-trial comparisons. Individual trials are included in the table  (<a class="graphic graphic_table graphicRef141033" href="/z/d/graphic/141033.html" rel="external">table 7</a>).</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">Ribociclib</a> and <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a> have both shown to improve OS when combined with <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> when compared with fulvestrant alone in patients who had prior ET (MONALEESA-3 and MONARCH 2) [<a href="#rid72">72,73</a>]; but the improvement in OS with the addition of <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">palbociclib</a> to fulvestrant did not reach statistical significance [<a href="#rid74">74</a>]. Further discussion on the toxicities associated with each CDK 4/6 inhibitor is found above. (See <a class="local">'Choosing between agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Strategies to avoid</strong> – The strategy of switching from one AI to another AI as monotherapy upon progression has shown mixed results, and we do not typically employ this strategy [<a href="#rid44">44,75</a>].</p><p></p><p class="headingAnchor" id="H2105452667"><span class="h3">For those previously treated on tamoxifen</span><span class="headingEndMark"> — </span>For those treated with <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> in the adjuvant setting, an AI with CDK 4/6 inhibition is preferred initial therapy for metastatic disease. The CDK 4/6 inhibitor trials discussed above included patients who were treated for de novo metastatic disease, as well as those who had experienced progression after adjuvant ET. (See <a class="local">'AIs plus CDK 4/6 inhibitors'</a> above.)</p><p>Although less preferable to the CDK 4/6 inhibitor-based combinations discussed above, single-agent AIs are available as subsequent-line therapy to those who seek a single-agent oral treatment, particularly if they have not received AIs in the frontline. There have been no differences in efficacy between the AIs in the second-line setting [<a href="#rid20">20,76,77</a>]. For example, in a phase III trial, 713 women with disease progression on prior <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> were randomly assigned to treatment with either <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a> or <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a> [<a href="#rid77">77</a>]. Although the ORR was significantly higher with letrozole (19 versus 12 percent), there was no significant difference in time to progression or OS.</p><p class="headingAnchor" id="H2036150368"><span class="h1">LATER-LINE THERAPY</span><span class="headingEndMark"> — </span>For women who progress after two lines of endocrine therapy (ET), treatment must be individualized based on their prior treatment response, tumor burden, and preferences for treatment. Options include the following:</p><p class="headingAnchor" id="H2662255127"><span class="h2">Chemotherapy</span><span class="headingEndMark"> — </span>In general, patients who have progressed after multiple lines of ET should receive chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer"</a>.)</p><p class="headingAnchor" id="H889467098"><span class="h2">Antibody drug-conjugates</span><span class="headingEndMark"> — </span>Antibody drug conjugates that may be used in select patients are discussed below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sacituzumab govitecan</strong> – <a class="drug drug_general" data-topicid="127999" href="/z/d/drug information/127999.html" rel="external">Sacituzumab govitecan</a> is an anti-Trop-2 antibody drug conjugate for patients with hormone receptor-positive, HER2-negative cancers after prior treatment including ET, a cyclin-dependent kinase (CDK) 4/6 inhibitor, and at least two lines of chemotherapy (including a taxane in either neo/adjuvant or advanced disease setting) for advanced breast cancer [<a href="#rid78">78,79</a>]. Its use is discussed in hormone receptor-positive cancers is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Sacituzumab govitecan'</a>.)</p><p></p><p class="bulletIndent1">Its role in triple-negative breast cancers is also discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer", section on 'Sacituzumab govitecan'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fam-trastuzumab deruxtecan</strong> – For patients with tumors that are either HER2 immunohistochemistry 1+, or 2+, and in situ hybridization negative, who have received at least one prior line of chemotherapy for metastatic disease and, if tumor is hormone receptor-positive, are refractory to ET, <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> is an appropriate option [<a href="#rid78">78</a>]. Further details and supporting data are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Sacituzumab govitecan'</a>.)</p><p></p><p class="headingAnchor" id="H977266071"><span class="h2">Other options</span><span class="headingEndMark"> — </span>For patients who are asymptomatic with slowly progressive disease, continuation of ET is reasonable, with one of the options below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tamoxifen</strong><strong> plus </strong><strong>abemaciclib</strong> – For patients without prior treatment with a CDK 4/6 inhibitor, the combination of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> plus <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a> has shown efficacy and tolerability, with improved outcomes over abemaciclib alone. In preliminary results of the phase II nextMONARCH study, patients randomly assigned to abemaciclib 150 mg plus tamoxifen 20 mg daily experienced a statistically significant improvement in median overall survival (OS), relative to those assigned to either abemaciclib 150 mg daily or abemaciclib 200 mg daily (24 months versus 21 and 17 months, respectively) [<a href="#rid80">80</a>]. Although patients were heavily pretreated, prior receipt of a CDK 4/6 inhibitor was an exclusion criterion for this trial.</p><p></p><p class="bulletIndent1">This trial shows that the addition of ET to a CDK 4/6 inhibitor is of value and also demonstrates a role for late introduction of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tamoxifen</strong><strong> monotherapy</strong> – Although we prefer other options over <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> for initial lines of ET, it may be an option in the later-line setting, recognizing that response rates are low. In the front-line setting, tamoxifen has yielded lower response rates relative to aromatase inhibitors (AIs), but similar OS; however, comparisons are not available for tamoxifen versus the combination of AIs and CDK 4/6 inhibitors, which is a more typical front-line regimen.</p><p></p><p class="bulletIndent1">In a meta-analysis of four randomized trials including 1560 postmenopausal women with hormone receptor-positive, advanced breast cancer, front-line treatment with AIs improved the clinical benefit rate (stable disease for &gt;24 weeks or response) compared with <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> (odds ratio [OR] 1.6), although the OS rate was similar between the two groups (OR 1.05) [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1">In a combined analysis of two randomized trials evaluating a sequence strategy (ie, <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> followed by <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a> or vice versa) in 1021 women, 511 were assigned to anastrozole, and of these, 137 women crossed over to tamoxifen [<a href="#rid82">82</a>]. Second-line treatment with tamoxifen in these women resulted in a 10 percent objective response rate and a clinical benefit rate of 49 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abemaciclib</strong> <strong>monotherapy</strong> – While CDK 4/6 inhibitors have been shown to combine effectively with ET, they also possess single-agent activity. The CDK 4/6 inhibitor <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a> is US Food and Drug Administration approved for use as monotherapy for women with progressive disease after ET and chemotherapy [<a href="#rid83">83</a>]. Its activity for patients who previously received a different CDK 4/6 inhibitor is unknown.</p><p></p><p class="bulletIndent1">In preliminary results from the phase II MONARCH 1 study, which enrolled 132 patients with a median of three prior lines of treatment (including one or two prior chemotherapy regimens in the metastatic setting), single-agent treatment with the novel CDK 4/6 inhibitor <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a> induced tumor response in 20 percent of patients, with a clinical benefit rate (stable or responding disease) of 42 percent, and median progression-free survival of six months [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormones</strong> <strong>or intermittent endocrine therapy</strong> – We choose other options before hormones for treatment of metastatic breast cancer, though historical reports suggested some activity and these strategies were used more frequently in the past [<a href="#rid85">85-94</a>]. The value of such approaches in contemporary practice, when most patients receive adjuvant anti-estrogen therapy, and when multiple endocrine treatments with and without targeted therapy options exist, is not known. Similarly, the historical literature include reports of treatment response to withdrawal of endocrine therapy [<a href="#rid95">95,96</a>]. While interruption or cessation of endocrine treatment is an option for patients with indolent tumors or those needing a break from therapy, such withdrawal responses are almost never encountered in contemporary practice. Both progestins and estrogens are associated with an increased risk of thromboembolic events, and their use should be avoided in patients with thromboembolic disorders or other risk factors for thromboembolic disease. (See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>.)</p><p></p><p class="headingAnchor" id="H506799227"><span class="h1">ADDITIONAL CONSIDERATIONS FOR PREMENOPAUSAL WOMEN</span><span class="headingEndMark"> — </span>For patients with metastatic hormone receptor-positive breast cancer, menopausal status must first be ascertained to determine the approach to treatment. (See <a class="local">'Ovarian suppression/ablation, in combination with ET'</a> below.)</p><p>We define menopause in women &lt;60 years using guidelines from the National Comprehensive Cancer Network [<a href="#rid97">97</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior bilateral oophorectomy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No menstrual periods in the preceding 12 or more months occurring either:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the absence of chemotherapy, <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> or <a class="drug drug_general" data-topicid="10164" href="/z/d/drug information/10164.html" rel="external">toremifene</a>, or ovarian suppression, or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>While undergoing treatment with chemotherapy, <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>, or <a class="drug drug_general" data-topicid="10164" href="/z/d/drug information/10164.html" rel="external">toremifene</a>, provided serum <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">estradiol</a> levels are in the postmenopausal range. (See  <a class="medical medical_review" href="/z/d/html/7402.html" rel="external">"Evaluation and management of secondary amenorrhea", section on 'Laboratory testing'</a>.)</p><p></p><p>Women who do not fit into the above categories are considered premenopausal, and as such, ovarian suppression/ablation becomes a consideration.</p><p class="headingAnchor" id="H3100133071"><span class="h2">Ovarian suppression/ablation, in combination with ET</span><span class="headingEndMark"> — </span>For premenopausal women treated with endocrine therapy (ET), we suggest concurrent ovarian suppression or ablation, in order to suppress estrogen levels. This is imperative for premenopausal patients receiving aromatase inhibitors (AIs), given the potential for ovarian stimulation with these agents.</p><p>Additionally, ovarian suppression allows premenopausal women to take advantage of the addition of targeted agents that have been evaluated in the postmenopausal setting, such as cyclin-dependent kinase (CDK) 4/6 inhibitors or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>. Once ovarian suppression or ablation is achieved, we follow a treatment approach as per postmenopausal women; for example, a regimen we commonly use for premenopausal women is a gonadotropin-releasing hormone agonist (GnRHa) plus the combination of an AI and a CDK 4/6 inhibitor. Data for CDK 4/6 inhibitors in premenopausal women are discussed here, while data in postmenopausal women are presented above. (See <a class="local">'Preferred first-line therapy'</a> above.)</p><p>Ovarian suppression and ablation have shown equivalent outcomes in clinical trials [<a href="#rid98">98</a>]. However, for women with disease progression on a regimen including ovarian suppression, some contributors assess serum <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">estradiol</a> levels to ensure menopausal status was achieved. If high estradiol levels are noted despite ovarian suppression, ovarian ablation should be performed. If estradiol is within the postmenopausal range, next-line therapy should be pursued.</p><p>In a randomized trial, the combination of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> and ovarian suppression with <a class="drug drug_general" data-topicid="8867" href="/z/d/drug information/8867.html" rel="external">buserelin</a> improved overall survival (OS) compared with treatment with either agent alone [<a href="#rid99">99</a>]. Furthermore, small studies have suggested that the addition of a GnRHa to an AI is as effective in premenopausal women as an AI alone is in postmenopausal women [<a href="#rid100">100,101</a>].</p><p class="headingAnchor" id="H1754773734"><span class="h3">Incorporation of targeted agents</span><span class="headingEndMark"> — </span>Available data in premenopausal patients suggest that a CDK 4/6 inhibitor may be effectively combined with ovarian suppression/ablation and <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> or an AI.</p><p>In MONALEESA-7, 672 pre- or perimenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer were randomly assigned to frontline <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">ribociclib</a> or placebo to be taken concurrently with <a class="drug drug_general" data-topicid="8500" href="/z/d/drug information/8500.html" rel="external">goserelin</a> and either <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> or a nonsteroidal AI. Progression-free survival (PFS) was improved with ribociclib (median PFS, 24 versus 13 months; hazard ratio [HR] 0.55, 95% CI 0.4-0.69) [<a href="#rid102">102</a>], as was the OS rate at 3.5 years (70 versus 46 percent; HR 0.71, 95% CI 0.54-0.95) [<a href="#rid14">14</a>]. The benefit of adding ribociclib was consistent across patient subgroups and regardless of the ET partner. Although this was the first trial to demonstrate an OS benefit with the addition of a CDK 4/6 inhibitor to ET, the observed benefits may be a class effect, as trials of other CDK 4/6 inhibitors have subsequently reported OS benefits, when combined with ET in postmenopausal women. (See <a class="local">'AIs plus CDK 4/6 inhibitors'</a> above.)</p><p>The most frequent all-grade adverse events were neutropenia (76 versus 8 percent), hot flashes (34 percent in each arm), nausea (32 versus 20 percent), leukopenia (31 versus 6 percent), and arthralgia (30 versus 27 percent). This trial was the basis of the US Food and Drug Administration approval of <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">ribociclib</a> with ET for pre-/perimenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.</p><p>Similarly, a CDK 4/6 inhibitor may effectively combine with <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> and ovarian suppression. Among the 108 premenopausal women with advanced ET-resistant disease in the PALOMA-3 trial, the addition of <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">palbociclib</a> to the combination of fulvestrant and <a class="drug drug_general" data-topicid="8500" href="/z/d/drug information/8500.html" rel="external">goserelin</a> improved the median PFS (9.5 versus 5.6 months; HR 0.50, 95% CI 0.29-0.87) and objective response rate (ORR; 25 versus 11.1 percent) [<a href="#rid103">103</a>]. Furthermore, in preliminary analysis of the pre-/perimenopausal subset of MONARCH 2, the addition of <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a> to fulvestrant and a GnRHa in a pretreated population of women with hormone receptor-positive, HER2-negative advanced breast cancer improved both PFS (not reached versus 10.5 months, respectively; HR 0.45, 95% CI 0.26-0.75) and ORR (61 versus 29 percent) relative to those receiving fulvestrant and a GnRHa [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H1392705641"><span class="h4">Versus chemotherapy</span><span class="headingEndMark"> — </span>For most premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, ET, with or without a targeted agent, is preferred over chemotherapy. This is the same approach as for postmenopausal women. (See  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Hormone receptor-positive, HER2-negative disease'</a>.)</p><p>In results of a randomized phase II study, among 184 premenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer, those assigned to <a class="drug drug_general" data-topicid="8920" href="/z/d/drug information/8920.html" rel="external">exemestane</a>, <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">palbociclib</a>, and a GnRHa experienced a better PFS than those assigned to <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> (20 versus 14 months; HR 0.66, 95% CI 0.44-0.99) [<a href="#rid105">105</a>]. Nonhematologic toxicities were less common with ET/palbociclib compared with capecitabine (eg, diarrhea, 13 versus 39 percent; hand-foot syndromes, 1 versus 100 percent, respectively), but hematologic toxicity was more common (grade ≥3 neutropenia, 64 versus 16 percent, respectively).</p><p class="headingAnchor" id="H1995215052"><span class="h2">Tamoxifen, as an alternative</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">Tamoxifen</a> is a selective estrogen receptor (ER) modulator (SERM) with mixed ER antagonistic and agonistic properties. It is principally antagonistic in breast cancer and breast tissue, as well as brain, whereas it has agonistic effects in bone, liver, and uterus. While our preference is for ovarian suppression or ablation plus ET, single-agent treatment with a SERM alone is an alternative for those who wish to avoid ovarian suppression. In a 1991 review of phase II trials of tamoxifen in premenopausal women, the ORR was 45 percent among the 31 patients with confirmed ER-positive disease [<a href="#rid106">106</a>].</p><p class="headingAnchor" id="H3185462822"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H1808361593"><span class="h2">BRCA mutation carriers</span><span class="headingEndMark"> — </span>For patients with metastatic HER2-negative breast cancer who have a germline breast cancer susceptibility gene (<em>BRCA</em>) mutation, the use of poly(ADP-ribose) polymerase inhibitors is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Special considerations'</a>.)</p><p class="headingAnchor" id="H931939338"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113775.html" rel="external">"Society guideline links: Breast cancer"</a>.)</p><p class="headingAnchor" id="H4108895112"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/865.html" rel="external">"Patient education: Treatment of metastatic breast cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H264716193"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Although metastatic breast cancer is unlikely to be cured, there have been meaningful improvements in survival due to advances in systemic therapy, including endocrine therapy (ET) and targeted agents. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – In patients with new metastatic disease, we biopsy a metastatic lesion to confirm estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status. We also assess for mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (<em>PIK3CA</em>), <em>AKT1, PTEN</em>,<em> </em>and <em>ESR1</em>, in tumor tissue and/or blood, for eligibility for AKT inhibitor, PI3K inhibitor, and <a class="drug drug_general" data-topicid="140691" href="/z/d/drug information/140691.html" rel="external">elacestrant</a>, respectively. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1">For most patients with hormone receptor-positive, HER2-negative metastatic breast cancer, we suggest initial treatment with ET plus targeted therapy, rather than chemotherapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). This includes patients with rapidly progressive, symptomatic disease or visceral metastases, although chemotherapy is an acceptable alternative. (See <a class="local">'Choosing between endocrine therapy and chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special considerations for those who received adjuvant ET</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Women who progress ≥12 months from the end of adjuvant ET and patients who present with de novo metastatic breast cancer are offered first-line endocrine-based therapies. (See <a class="local">'Preferred first-line therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Those who progress on or within 12 months of completing adjuvant ET are eligible for subsequent-line endocrine-based therapies. Patients who progress on first-line ET for metastatic disease are also eligible for subsequent-line treatment. (See <a class="local">'Subsequent-line options'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For initial therapy for patients with metastatic hormone receptor-positive, HER2-negative breast cancer, we suggest a cyclin-dependent kinase (CDK) 4/6 inhibitor in combination with an aromatase inhibitor (AI) rather than an AI alone (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). However, other acceptable options include single-agent <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> or <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a>, or fulvestrant in combination with an AI.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For premenopausal women treated with ET, we suggest concurrent ovarian suppression or ablation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This is imperative for premenopausal patients receiving AIs, given the potential for ovarian stimulation with these agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent-line treatment</strong> – For patients who have previously experienced progression on an AI and CDK 4/6 inhibitor, our approach is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those harboring alterations in <em>PIK3CA</em>, <em>AKT1</em>, or <em>PTEN</em>, we suggest the combination of <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> with <a class="drug drug_general" data-topicid="143510" href="/z/d/drug information/143510.html" rel="external">capivasertib</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Fulvestrant with the alpha isoform-specific PI3K inhibitor <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">alpelisib</a> is an alternative option for<em> PIK3CA</em>-mutant breast cancer. For those with coexisting <em>ESR1</em> mutations, <a class="drug drug_general" data-topicid="140691" href="/z/d/drug information/140691.html" rel="external">elacestrant</a> is a reasonable alternative especially if patients had a prolonged progression-free survival on prior ET with a CDK 4/6 inhibitor. (See <a class="local">'Alterations in PIK3CA, AKT1, or PTEN'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with <em>PIK3CA</em>-wild-type cancers,</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the tumor is <em>ESR1</em> wild-type, options include <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> monotherapy or everolimus-based combinations, with a choice between them driven by side-effect profiles. (See <a class="local">'ESR1 wild-type'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If an <em>ESR1</em> mutation is present, we suggest <a class="drug drug_general" data-topicid="140691" href="/z/d/drug information/140691.html" rel="external">elacestrant</a> rather than <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">fulvestrant</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Fulvestrant, with or without <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, is a reasonable alternative. (See <a class="local">'ESR1 mutation-positive'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Later-line treatment</strong> – For patients who have progressed on two or more lines of ET, a switch to chemotherapy may be appropriate. However, for patients who are asymptomatic with slowly progressive disease, continuation of ET is reasonable, and <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> may be an appropriate later-line option. (See <a class="local">'Later-line therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H2920272300"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Matthew Ellis, MD, PhD, FRCP; Michael J Naughton, MD; and Maura Dickler, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31:1623.</a></li><li><a class="nounderline abstract_t">Lindström LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30:2601.</a></li><li><a class="nounderline abstract_t">Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022; 40:1231.</a></li><li><a class="nounderline abstract_t">Liu MC, MacKay M, Kase M, et al. Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer. JCO Precis Oncol 2022; 6:e2100321.</a></li><li><a class="nounderline abstract_t">Burstein HJ, DeMichele A, Somerfield MR, et al. Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2023; 41:3423.</a></li><li><a class="nounderline abstract_t">Martin M, Zielinski C, Ruiz-Borrego M, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann Oncol 2021; 32:488.</a></li><li><a class="nounderline abstract_t">Kahan Z, Gil-Gil M, Ruiz-Borrego M, et al. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. Eur J Cancer 2021; 156:70.</a></li><li><a class="nounderline abstract_t">Lu YS, Mahidin E, Azim H, et al. GS1-10 Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. SABCS 2022.</a></li><li><a class="nounderline abstract_t">Sledge GW Jr, Hu P, Falkson G, et al. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2000; 18:262.</a></li><li><a class="nounderline abstract_t">Gao JJ, Cheng J, Bloomquist E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol 2020; 21:250.</a></li><li><a class="nounderline abstract_t">Li J, Huo X, Zhao F, et al. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open 2020; 3:e2020312.</a></li><li><a class="nounderline abstract_t">Sonke G, van Ommen A, Wortelboer N, et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). J Clin Oncol 2023; 41, 17S. LBA1000.</a></li><li><a class="nounderline abstract_t">Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 2022; 386:942.</a></li><li><a class="nounderline abstract_t">Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381:307.</a></li><li><a class="nounderline abstract_t">Finn RS, Rugo HS, Dieras VC, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. J Clin Oncol 2022; 40S:ASCO #LBA1003.</a></li><li><a class="nounderline abstract_t">Rugo H, et al. Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis. Ann Oncol 2022; 33 (S3): S194-S223.</a></li><li><a class="nounderline abstract_t">Goetz MP. MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer. SABCS 2023; GS01-12.</a></li><li class="breakAll">Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. Cell Chemical Biology. Available at: https://www.cell.com/cell-chemical-biology/pdf/S2451-9456(19)30174-6.pdf.</li><li><a class="nounderline abstract_t">Zhang P, Zhang Q, Tong Z, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2023; 24:646.</a></li><li><a class="nounderline abstract_t">Campos SM, Guastalla JP, Subar M, et al. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009; 9:39.</a></li><li><a class="nounderline abstract_t">Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20:751.</a></li><li><a class="nounderline abstract_t">Sainsbury R. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? Br J Cancer 2004; 90:1733.</a></li><li><a class="nounderline abstract_t">DeFriend DJ, Anderson E, Bell J, et al. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer 1994; 70:204.</a></li><li><a class="nounderline abstract_t">Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993; 106 ( Pt 4):1377.</a></li><li><a class="nounderline abstract_t">DeFriend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994; 54:408.</a></li><li><a class="nounderline abstract_t">Robertson JF, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 2016; 388:2997.</a></li><li><a class="nounderline abstract_t">Howell A, Pippen J, Elledge RM, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005; 104:236.</a></li><li><a class="nounderline abstract_t">Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003; 98:229.</a></li><li><a class="nounderline abstract_t">Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008; 26:1664.</a></li><li><a class="nounderline abstract_t">Mauriac L, Romieu G, Bines J. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res Treat 2009; 117:69.</a></li><li><a class="nounderline abstract_t">Llombart-Cussac A, Pérez-García JM, Bellet M, et al. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol 2021; 7:1791.</a></li><li><a class="nounderline abstract_t">Gao JJ, Cheng J, Prowell TM, et al. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. Lancet Oncol 2021; 22:1573.</a></li><li><a class="nounderline abstract_t">Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367:435.</a></li><li><a class="nounderline abstract_t">Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012; 30:1919.</a></li><li><a class="nounderline abstract_t">Johnston SR, Kilburn LS, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 2013; 14:989.</a></li><li><a class="nounderline abstract_t">Mehta RS, Barlow WE, Albain KS, et al. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. N Engl J Med 2019; 380:1226.</a></li><li><a class="nounderline abstract_t">Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006; 98:1285.</a></li><li><a class="nounderline abstract_t">Fribbens C, O'Leary B, Kilburn L, et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol 2016; 34:2961.</a></li><li><a class="nounderline abstract_t">Chandarlapaty S, Chen D, He W, et al. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol 2016; 2:1310.</a></li><li><a class="nounderline abstract_t">Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 2014; 106:djt337.</a></li><li><a class="nounderline abstract_t">Kornblum N, Zhao F, Manola J, et al. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. J Clin Oncol 2018; 36:1556.</a></li><li><a class="nounderline abstract_t">Schmid P, Zaiss M, Harper-Wynne C, et al. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncol 2019; 5:1556.</a></li><li><a class="nounderline abstract_t">Jhaveri K, Eli LD, Wildiers H, et al. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol 2023; 34:885.</a></li><li><a class="nounderline abstract_t">Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520.</a></li><li><a class="nounderline abstract_t">Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol 2014; 25:2357.</a></li><li><a class="nounderline abstract_t">Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30:2718.</a></li><li><a class="nounderline abstract_t">Mayer EL, Ren Y, Wagle N, et al. Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer. SABCS 2022.</a></li><li><a class="nounderline abstract_t">llombart-cussac A, Harper-wynne C, Perello A, et al. Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. J Clin Oncol 2023; S16; abst 1001.</a></li><li class="breakAll">ORSERDU (elacestrant) tablets, for oral use. United States Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf (Accessed on January 30, 2023).</li><li><a class="nounderline abstract_t">Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2022; 40:3246.</a></li><li><a class="nounderline abstract_t">Bardia A, Bidard FC, Neven P, et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy. SABCS 2022.</a></li><li><a class="nounderline abstract_t">Bidard FC, Hardy-Bessard AC, Dalenc F, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2022; 23:1367.</a></li><li><a class="nounderline abstract_t">Goetz MP, Bagegni NA, Batist G, et al. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol 2023; 34:1141.</a></li><li><a class="nounderline abstract_t">Damodaran S, O'Sullivan CC, Elkhanany A, et al. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol 2023; 34:1131.</a></li><li><a class="nounderline abstract_t">Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61.</a></li><li class="breakAll">TRUQAP (capivasertib) tablets, for oral use. US Prescribing Information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf (Accessed on December 12, 2023).</li><li><a class="nounderline abstract_t">Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2023; 388:2058.</a></li><li><a class="nounderline abstract_t">Howell SJ, Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol 2022; 23:851.</a></li><li><a class="nounderline abstract_t">André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380:1929.</a></li><li><a class="nounderline abstract_t">André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2021; 32:208.</a></li><li><a class="nounderline abstract_t">Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 2021; 22:489.</a></li><li><a class="nounderline abstract_t">Rugo HS, Lacouture ME, Goncalves MD, et al. A multidisciplinary approach to optimizing care of patients treated with alpelisib. Breast 2022; 61:156.</a></li><li class="breakAll">Metformin (MET) for the prevention of Alpelisib (ALP)-related hyperglycemia (HG) in PIK3CA-mutated, hormone receptor-positive (HR[+]) HER2-negative (HER2[-]) advanced breast cancer (ABC): The METALLICA study. Larvol Clin Cancer Trial Results. Available at: https://clin.larvol.com/abstract-detail/SABCS%202022/60535107 (Accessed on February 11, 2023).</li><li><a class="nounderline abstract_t">Jhaveri KL, Im S-A, Saura C, et al. Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis. SABCS 2023; Abstract GS03-13.</a></li><li><a class="nounderline abstract_t">Cochrane DR, Bernales S, Jacobsen BM, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 2014; 16:R7.</a></li><li><a class="nounderline abstract_t">Dickler MN, Barry WT, Cirrincione CT, et al. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol 2016; 34:2602.</a></li><li><a class="nounderline abstract_t">Martín M, Loibl S, von Minckwitz G, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol 2015; 33:1045.</a></li><li><a class="nounderline abstract_t">Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2016; 17:811.</a></li><li><a class="nounderline abstract_t">Baselga J, Dent SF, Cortes J, et al. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. J Clin Oncol 2018; 36S: ASCO #1006.</a></li><li><a class="nounderline abstract_t">Dent S, Cortés J, Im YH, et al. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol 2021; 32:197.</a></li><li><a class="nounderline abstract_t">Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol 2019; 20:1360.</a></li><li><a class="nounderline abstract_t">Sledge GW Jr, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2020; 6:116.</a></li><li><a class="nounderline abstract_t">Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382:514.</a></li><li><a class="nounderline abstract_t">Turner NC, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med 2018; 379:1926.</a></li><li><a class="nounderline abstract_t">Beresford M, Tumur I, Chakrabarti J, et al. A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin Oncol (R Coll Radiol) 2011; 23:209.</a></li><li><a class="nounderline abstract_t">Dixon JM, Renshaw L, Langridge C, et al. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. Breast Cancer Res Treat 2011; 125:741.</a></li><li><a class="nounderline abstract_t">Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003; 39:2318.</a></li><li><a class="nounderline abstract_t">Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20:691.</a></li><li><a class="nounderline abstract_t">Rugo H, Bardia A, Marme F, et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol 2022; LBA1001.</a></li><li><a class="nounderline abstract_t">Hamilton EP, Cortes J, Ozyilkan O, et al. nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer. Ann Oncol 2020; 31S: ESMO #273O.</a></li><li><a class="nounderline abstract_t">Robertson JFR, Paridaens RJ, Lichfield J, et al. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. Eur J Cancer 2021; 145:19.</a></li><li><a class="nounderline abstract_t">Thürlimann B, Robertson JF, Nabholtz JM, et al. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003; 39:2310.</a></li><li class="breakAll">Abemaciclib tablets. Unites States Prescribing Information. US National Library of Medicine. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf (Accessed on March 20, 2018).</li><li><a class="nounderline abstract_t">Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res 2017; 23:5218.</a></li><li><a class="nounderline abstract_t">Abrams J, Aisner J, Cirrincione C, et al. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J Clin Oncol 1999; 17:64.</a></li><li><a class="nounderline abstract_t">Willemse PH, van der Ploeg E, Sleijfer DT, et al. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer 1990; 26:337.</a></li><li><a class="nounderline abstract_t">Kornblith AB, Hollis DR, Zuckerman E, et al. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. J Clin Oncol 1993; 11:2081.</a></li><li><a class="nounderline abstract_t">Mattsson W. Current status of high dose progestin treatment in advanced breast cancer. Breast Cancer Res Treat 1983; 3:231.</a></li><li><a class="nounderline abstract_t">Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009; 302:774.</a></li><li><a class="nounderline abstract_t">Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304:16.</a></li><li><a class="nounderline abstract_t">GOLDENBERG IS. RESULTS OF STUDIES OF THE COOPERATIVE BREAST CANCER GROUP--1961-63. Cancer Chemother Rep 1964; 41:SUPPL:1.</a></li><li><a class="nounderline abstract_t">Coombes RC, Dearnaley D, Humphreys J, et al. Danazol treatment of advanced breast cancer. Cancer Treat Rep 1980; 64:1073.</a></li><li><a class="nounderline abstract_t">Manni A, Arafah BM, Pearson OH. Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. Cancer 1981; 48:2507.</a></li><li><a class="nounderline abstract_t">Schifeling DJ, Jackson DV, Zekan PJ, Muss HB. Fluoxymesterone as third line endocrine therapy for advanced breast cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol 1992; 15:233.</a></li><li><a class="nounderline abstract_t">Fan L, Liedke PE, Isakoff SJ, et al. Intermittent letrozole therapy for metastatic breast cancer: case reports and literature review. Clin Breast Cancer 2014; 14:e41.</a></li><li><a class="nounderline abstract_t">Chavarri-Guerra Y, Higgins MJ, Szymonifka J, et al. Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy. Br J Cancer 2014; 111:2046.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology: Breast cancer. Version 4.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Accessed on September 29, 2023).</li><li><a class="nounderline abstract_t">Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 1998; 16:994.</a></li><li><a class="nounderline abstract_t">Klijn JG, Beex LV, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000; 92:903.</a></li><li><a class="nounderline abstract_t">Carlson RW, Theriault R, Schurman CM, et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 2010; 28:3917.</a></li><li><a class="nounderline abstract_t">Park IH, Ro J, Lee KS, et al. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol 2010; 28:2705.</a></li><li><a class="nounderline abstract_t">Tripathy D, Sohn J, Im S-A, et al. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women. Cancer Res 2017; 77S: SABCS #GS2-05.</a></li><li><a class="nounderline abstract_t">Loibl S, Turner NC, Ro J, et al. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist 2017; 22:1028.</a></li><li><a class="nounderline abstract_t">Neven P, Rugo HS, Tolaney SM, et al. Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer. J Clin Oncol 2018; 36S: ASCO #1002.</a></li><li><a class="nounderline abstract_t">Park YH, Kim TY, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2019; 20:1750.</a></li><li><a class="nounderline abstract_t">Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 1991; 9:1283.</a></li></ol></div><div id="topicVersionRevision">Topic 778 Version 111.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32979513" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22711854" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35721584" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37196213" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33385521" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34425406" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : GS1-10 Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2−advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10637238" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31859246" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33048129" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35263519" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31166679" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2−ABC): Analyses from PALOMA-2</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37182538" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19299239" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821457" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150604" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8054267" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8126115" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8275477" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27908454" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15937908" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12872340" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316794" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19030986" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34617955" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34656225" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22853014" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Combination anastrozole and fulvestrant in metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22370325" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23902874" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30917258" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16985247" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27269946" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27532364" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24317176" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29664714" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31465093" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37597578" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22149876" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25231953" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22565002" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35584336" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36183733" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38072514" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38072513" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23000897" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comprehensive molecular portraits of human breast tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23000897" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comprehensive molecular portraits of human breast tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37256976" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35671774" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31091374" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33246021" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33794206" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35016012" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A multidisciplinary approach to optimizing care of patients treated with alpelisib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35016012" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A multidisciplinary approach to optimizing care of patients treated with alpelisib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24451109" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27138575" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25691671" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27155741" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33186740" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31494037" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31563959" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31826360" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30345905" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134732" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20821047" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14556923" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35714673" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33418233" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14556922" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14556922" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28533223" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10458219" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2141491" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8229122" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6225476" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Current status of high dose progestin treatment in advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19690310" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7001242" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14213144" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : RESULTS OF STUDIES OF THE COOPERATIVE BREAST CANCER GROUP--1961-63.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7459893" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Danazol treatment of advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7296499" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1590276" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Fluoxymesterone as third line endocrine therapy for advanced breast cancer. A phase II trial of the Piedmont Oncology Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24342729" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Intermittent letrozole therapy for metastatic breast cancer: case reports and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25233398" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25233398" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9508182" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10841825" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20679610" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421538" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28652278" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31668850" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2045868" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Tamoxifen in premenopausal patients with metastatic breast cancer: a review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
